Medpace vs Maxcyte: revenue, profit, margins and growth compared
Medpace brought in $2.5B of revenue in fiscal 2025, Maxcyte $33M in fiscal 2025. Revenue changed by +20.0% at Medpace and -14.5% at Maxcyte on the year before, so Medpace grew faster. Medpace kept 17.8% of its revenue as net profit, Maxcyte -135.1%. Free cash flow was $681.9M at Medpace and -$36.2M at Maxcyte.
Fiscal years as each company reports them; the two may end in different months.
Questions about Medpace and Maxcyte
Which is bigger by revenue, Medpace or Maxcyte?
Medpace is bigger by revenue: $2.5B in fiscal 2025, against $33M for Maxcyte in fiscal 2025.
Which keeps more of its revenue as profit, Medpace or Maxcyte?
Medpace had a net margin of 17.8% in fiscal 2025; Maxcyte had -135.1% in fiscal 2025.
Which grew revenue faster, Medpace or Maxcyte?
In their latest fiscal years revenue changed by +20.0% at Medpace and -14.5% at Maxcyte.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.